Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes

The integrase inhibitor (INI) dolutegravir (DTG; S/GSK1349572) has significant activity against HIV-1 isolates with raltegravir (RAL)- and elvitegravir (ELV)-associated resistance mutations. As an initial step in characterizing the different resistance profiles of DTG, RAL, and ELV, we determined th...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Hightower, Kendra E., Wang, Ruolan, DeAnda, Felix, Johns, Brian A., Weaver, Kurt, Shen, Yingnian, Tomberlin, Ginger H., Carter, H. Luke, Broderick, Timothy, Sigethy, Scott, Seki, Takahiro, Kobayashi, Masanori, Underwood, Mark R.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society for Microbiology 2011
Aiheet:
Antiviral Agents
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3187001/
https://ncbi.nlm.nih.gov/pubmed/21807982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00157-11
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia